Immunovant IMVT
United StatesHealthcare · BiotechnologyUSD
48.88 USD (+52.5%)
16 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Immunovant is a clinical-stage biopharmaceutical company developing anti-FcRn antibody therapies for the treatment of autoimmune diseases mediated by pathogenic antibodies.
Key points
from its scores- ✓Good share-price trend9.8
- ✕Little or no dividend0.5
- ✕Little competitive advantage0.8
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsHigh-risk, high-reward stock: only suitable for investors with high risk tolerance who believe in the potential of its pipeline and are willing to overlook the lack of current fundamentals.
Immunovant is a development-stage biotech with no revenue, a healthy balance sheet (liquidity 7.27, net debt/EBITDA 1.41) and strong stock momentum (119.38), but with very negative profitability (ROE -80.1%) and a valuation that depends entirely on the success of its clinical pipeline.
The main risk is regulatory and clinical development: failure of its lead drug candidate in ongoing trials could destroy most of the company's value, given it has no revenue or approved products.
Context and risks
Development-stage biotech with no revenue or profits, with an ROE of -80.1% and an operating margin of 0%. The main risk is regulatory and business model: it depends on the success of its clinical trials and FDA approval for its lead drug candidate. The stock's price volatility (beta 7.16) reflects this uncertainty, which is not captured by financial metrics.
Is Immunovant stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 9.0 | 4.1 | +119% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 48.88 USD, +52.5% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −11.7
- EV / EBITDA
- −10.3
- Price / book
- 9.0
- Market cap
- 6.6B USD
- Enterprise value
- 5.8B USD
Profitability
- ROE
- −80.1%
- ROA
- −46.7%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Free cash flow
- −238.7M USD
- FCF yield
- −3.6%
Solvency
- Total debt
- 0 USD
- Net debt
- −797.8M USD
- Cash
- 797.8M USD
- EBITDA
- −565.6M USD
- Net debt / EBITDA
- 1.41
- Current ratio
- 7.27
- Quick ratio
- 6.82
Growth
- EPS (TTM)
- −2.82 USD
- EPS (forward)
- −2.75 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.84
- Analyst consensus
- Buy (16)
- Target price
- 48.88 USD
- 52-week range
- 16.08 – 45.42
Recent news
All IMVT news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Immunovant
Is Immunovant stock cheap or expensive?
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 48.88 USD, +52.5% versus the price. This is not investment advice.
What score does Immunovant get on MeridIAn Screener?
It scores 3.2 out of 10, rank 2,063 of 2,130 (better than 3% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Immunovant worth on the stock market?
Its market capitalisation is 6.6B USD and its enterprise value, debt included, is 5.8B USD.
How much debt does Immunovant have?
It has more cash than debt: net cash of 797.8M USD.
Does Immunovant pay a dividend?
It pays no dividend, or almost none.
How has Immunovant stock performed over the last year?
It has risen 88.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 16.08 and 45.42 USD. Past performance does not guarantee future results.
What do analysts think of Immunovant?
16 analysts cover it; their average recommendation is “Buy” and their average target is 48.88 USD (+52.5% versus the price). It is an estimate, not market data.